Story thread · 2 reports / 2 sources

FDA suggests regulatory flexibility for assessing psychedelics

endpts.com · 4dShare

FDA regulators said they’re open to “innovative approaches” for studying the effects of psychedelic therapies, including the use of comparators other than placebo. The comments echo recently finalized regulatory guidance and signal ...

First report: FDA Is Open to Novel Approaches for Evaluating Psychedelics — bloomberg.com, 5d